From a recent study, it was evaluated that erenumab is effective to treat patients with episodic migraine. It was depicted that Erenumab treatment groups attained better monthly migraine days (MMD) responses than placebo.

This study was aimed to find the efficacy of erenumab at the ≥50%, ≥75%, and 100% decrease in MMD response thresholds.

In this study, the efficiency of erenumab at ≥50%, ≥75%, and 100% fall in MMD response thresholds was evaluated. Patients with episodic migraine were randomized into the ratio of 1:1:1 to erenumab 70 mg, erenumab 140 mg or placebo once monthly. 

Patients who executed responses at the ≥50%, ≥75%, or 100% thresholds showed greater drops in migraine days and in migraine-specific medicines use as well as considerable progress in headache impact and migraine-related disability and as determined by the decrease in mMIDAS, HIT-6 and MPFID test scores as compared with the general erenumab-treated people. 

Table- Showing response threshold 

The administration of erenumab worked effectively for patients with episodic migraine.